Exploring the Multifaceted Role of Microbes in Pharmacology
With the continuous growth in human population, rising incidence and predominance of various diseases, there is growing need for development of natural as well as engineered diagnostic systems and drugs in order to meet the therapeutic demands. Since microorganisms have evolved in nature with an astounding set of mechanisms utilized in detecting and responding to varied, transient and enduring external stimuli, such microbial systems can be utilized in diagnosis as well as giving competition to animal cells in producing value added products due to its easy and low cost processing. The re-making of various biosensing systems by incorporating whole cells intend to provide efficient biological detection and measurable response. Microbes governing the synthesis of biopolymers are also found to be exploited in developing new generation of novel drug delivery systems and as repair material of tissues. The area of synthetic biology together with novel microbial systems and whole cells is gaining rapid attention in diagnostics and global health challenges. With this background, the present chapter highlights various applications of microbes in pharmaceutical industries with special emphasis on diagnosis and drug delivery.
KeywordsAntibiotics Drug delivery Enzyme inhibitor Microbes
The authors are thankful to Director, MNNIT Allahabad for providing necessary research facilities and acknowledge the support of MHRD sponsored project “Design and Innovation Centre” and Centre for Medical Diagnostic and Research (CMDR), MNNIT Allahabad.
- Bleckwenn NA, Shiloach J (2004) Large-scale cell culture. Curr Protoc Immunol. A-1UGoogle Scholar
- Borowitzka MA, Borowitzka LJ (1988) Micro-algal biotechnology. Cambridge University Press, New YorkGoogle Scholar
- Buss AD, Waigh RD (1995) Natural products as leads for new pharmaceuticals. In: Wolff ME (ed) Burger’s medicinal chemistry and drug discovery. Principles and practice, vol 1. Wiley, New York, pp 983–1033Google Scholar
- Harrigan GG, Yoshida WY, Moore RE, Nagle DG, Park PU, Biggs J, Paul VJ, Mooberry SL, Corbett TH, Valeriote FA (1998) Isolation, structure determination, and biological activity of dolastatin and lyngbyastatin 1 from Lyngbyamajuscula/Schizothrixcalcicola cyanobacterial assemblages. J Nat Prod 61:1221–1225CrossRefPubMedGoogle Scholar
- Harrison L, Teplow DB, Rinaldi M, Strobel G (1991) Pseudomycins, a family of novel peptides from Pseudomonas syringae possessing broad-spectrum antifungal activity. Microbiology 137:2857–2865Google Scholar
- Hoffmann S, Maculloch B, Batz M (2015) Economic burden of major foodborne illnesses acquired in the United States. USDA-140. GPO, Washimhton, DCGoogle Scholar
- Luesch H, Moore RE, Paul VJ, Mooberry SL, Corbett TH (2001) Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J Nat Prod 64:610–907Google Scholar
- Nissim A, Chernajovsky Y (2008) Historical development of monoclonal antibody therapeutics. In: Therapeutic antibodies. Springer, Berlin, pp 3–18Google Scholar
- Redwan ERM (2007) Cumulative updating of approved biopharmaceuticals. Hum Antibodies 16:137–158Google Scholar